--- title: "Primary biliary cholangitis: Disease burden, treatments and RWD gaps" description: "Primary biliary cholangitis: understanding the disease, treatment landscape, current drugs used to treat or manage primary biliary cholangitis, and RWD." image: https://blog.healthverity.com/hubfs/primary-biliary-cholangitis-featured.png --- Announcing HealthVerity Precision Event Alerts, a next-generation physician alerting solution. [Learn more](https://healthverity.com/news/healthverity-precision-event-alerts-launch/) - [Contact](https://healthverity.com/contact/) - [Sign In](https://marketplace.healthverity.com/login/?next=/marketplace/) [![HealthVerity-Logo-Dark-3](https://blog.healthverity.com/hs-fs/hubfs/HealthVerity-Logo-Dark-3.png?width=1662&height=320&name=HealthVerity-Logo-Dark-3.png)](https://healthverity.com/) - How We Help - Featured Content - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Life Sciences](https://healthverity.com/life-sciences/) - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - Data Ecosystem - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Precision Event Alerts](https://healthverity.com/precision-event-alerts/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/portal/) - [Media Measurement](https://healthverity.com/media-measurement/) - [Insurance Underwriting](https://healthverity.com/insurance-underwriting/) - Technology Products - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - [HealthVerity FLOW](https://healthverity.com/flow/portal/) - [Governance Manager](https://healthverity.com/governance-manager/) - [Smart Contracts](https://healthverity.com/smart-contracts-manager/) - Symphony - Symphony Health Platform - [Symphony Health Overview](https://healthverity.com/symphony-health/overview/) - [Integrated Dataverse](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - Symphony Solutions - [Health technology and business intelligence solutions](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Integrated Dataverse and Source Solutions](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Brand strategy and sales](https://healthverity.com/symphony-health/optimize-brand-strategy-and-sales-effectiveness/) - [HealthRankings](https://healthverity.com/symphony-health/health-rankings/) - [Market access](https://healthverity.com/symphony-health/solve-market-access-challenges/) - [Patient Journey](https://healthverity.com/symphony-health/understand-the-patient-journey/) - [Medicines affordability](https://healthverity.com/symphony-health/making-medicines-more-affordable/) - Symphony Products - [PayerSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PayerSource.pdf) - [PrescriberSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PrescriberSource.pdf) - [PatientSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSource.pdf) - [PatientSourceCompleteTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceComplete.pdf) - [PatientSourceDUOTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceDUO.pdf) - [Symphony FLEXTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Symphony-FLEX.pdf) - [CustomerSource®](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [DiagnosticSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-DiagnosticSource.pdf) - [NonRetailSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-NonRetailSource.pdf) - Symphony Technology - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Synoma Data Integration](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Vantage Applications](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Vantage-Applications.pdf) - [Metys](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/metys/) - Who We Serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) - Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) - [Zombie Data Explained](https://healthverity.com/get-verified/) - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) [Contact](https://healthverity.com/contact/) [Sign In](https://marketplace.healthverity.com/) [![Logo](https://blog.healthverity.com/hubfs/social-suggested-images/healthverity.comwp-contentuploadshealthverity-2023-logo2x.png)](https://healthverity.com/) - How We Help - Symphony - Who We Serve - Resources - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) Featured Content ###### HealthVerity MarketplaceTM The nation’s largest healthcare and consumer data ecosystem ###### taXonomy Pathways Unique features per therapeutic area with claims, labs and EHR including notes ###### HealthVerity eXOs AI-native real-world evidence generation ###### Identity Manager (HVID) Standalone de-identification as a service Data Ecosystem HealthVerity MarketplaceTM HealthVerity TaxonomySM HealthVerity Notes Precision Event Alerts HealthVerity Mastersets Media Measurement Syndicated Audiences Insurance Underwriting Technology Products Identity Manager (HVID) HealthVerity for Clinical Trial Linkage HealthVerity for Commercial Smart Contracts HealthVerity for Registries Symphony Health Platform ###### Symphony Health Overview Seamless Data. Stronger Insights. Smarter Decisions. ###### Integrated Dataverse Integrated Dataverse (IDV®) is de-identified claims data platform that combines medical, hospital, prescription, and demographic data into a single unifed view. ###### Symphony HealthCloud Securely store, integrate, access, and analyze virtually unlimited volumes of data with Symphony HealthCloud. Symphony Solutions Health technology and business intelligence solutions Integrated Dataverse and Source Solutions Brand strategy and sales HealthRankings Market access Patient Journey Medicines affordability Symphony Products PayerSource® PrescriberSource® PatientSource® PatientSourceCompleteTM PatientSourceDUOTM Symphony FLEXTM CustomerSource® DiagnosticSource® NonRetailSource® Symphony Technology Symphony HealthCloud Synoma Data Integration Vantage Applications Metys ###### Life Sciences Technology solutions from development through commercialization ###### Channel Partners HealthVerity enables partners to unlock unprecedented value and insights for clients ###### Government Comprehensive and compliant solutions to manage the nation’s care ###### Data Ecosystem Partners Join the nation’s largest data partner ecosystem ###### Insurance Insurance-grade solutions that excel in managing risk and rebates ###### HealthVerity Blog Insights and updates from industry experts ###### Publications Peer-reviewed research and discoveries ###### News & Events Stay informed about our latest announcements and happenings ###### The IPGE Approach Fundamentals that power everything that we do and every solution we offer ###### Resource Library Explore guides, webinars, and tools to enhance your understanding ###### Zombie Data Explained Learn how data quality drives better research outcomes [Marketplace (RWD)](https://blog.healthverity.com/tag/marketplace-rwd), [Rare Diseases](https://blog.healthverity.com/tag/rare-diseases) # Primary biliary cholangitis: Disease burden, treatments and RWD gaps [By \- HealthVerity,](https://blog.healthverity.com/author/healthverity) January 23, 2026 ![Primary biliary cholangitis in the real world: Disease burden, treatments and gaps](https://blog.healthverity.com/hubfs/primary-biliary-cholangitis-featured.png) ## What real-world data reveals about the unique challenges of studying rare disease Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease marked by immune-mediated damage to the small bile ducts inside the liver. Over time, that injury can lead to cholestasis (reduced bile flow), progressive scarring, cirrhosis, and in advanced cases, liver failure or transplant.1-4 PBC is considered a rare disease, but its impact is not small. A 2025 systematic review and meta-analysis estimated a pooled global prevalence of 18.1 cases per 100,000 people and an incidence of 1.8 per 100,000 person-years, with higher prevalence among women and variation by geography.3 In the United States, population estimates also show a strong sex disparity. NIDDK summarizes that in 2014, prevalence was estimated at 58 per 100,000 women and 15 per 100,000 men, and the average age at diagnosis was about 60.1 Many patients are diagnosed after routine labs show a cholestatic pattern, then confirmed with disease-specific antibodies (often antimitochondrial antibodies) and clinical evaluation.4 Symptoms vary, and can include fatigue and pruritus, with some patients remaining relatively asymptomatic for long periods.4 ## Current drugs used to treat or manage primary biliary cholangitis The PBC treatment landscape **has shifted quickly** in the past two years, which has real implications for evidence generation. - **Ursodeoxycholic acid (UDCA/ursodiol)** remains foundational therapy and is recommended in major guidelines.4 It is used to slow disease progression and improve outcomes for many patients.2,4 - **Elafibranor (IQIRVO)** received FDA accelerated approval for adults with PBC who have an inadequate response to UDCA, or as monotherapy in patients who cannot tolerate UDCA. - **Seladelpar (LIVDELZI)** also received FDA accelerated approval for a similar population: adults with an inadequate response to UDCA, or as monotherapy when UDCA is not tolerated. - **❌ Obeticholic acid (Ocaliva)** was rapidly pulled from the market in 2025 after real-world data identified serious liver injury risks in some patients.5-7 Obeticholic acid (Ocaliva) illustrates why this matters. Post-approval real-world experience identified serious liver injury risks in some patients without cirrhosis, prompting an FDA Drug Safety Communication in late 2024 and a voluntary U.S. market withdrawal in 2025.5-7 The withdrawal of obeticholic acid from the U.S. market created a **therapeutic disruption** for patients with an inadequate response or intolerance to ursodeoxycholic acid, while the 2024 approval of seladelpar introduced a new second-line option into routine practice (Figure 1). This rapid transition has shifted real-world treatment pathways faster than traditional evidence generation can adapt, increasing the need for timely, longitudinal data to understand how patients are switching therapies, how biochemical response evolves outside trials, and where unmet need persists.   ![](https://blog.healthverity.com/hs-fs/hubfs/undefined-Jan-20-2026-07-39-54-2633-PM.png?width=747&height=385&name=undefined-Jan-20-2026-07-39-54-2633-PM.png) **Figure 1:** Real-world data suggest seladelpar may be a suitable option for PBC patients switching from obeticholic acid and as second-line therapy, though longer-term follow-up is needed to fully characterize outcomes. Created using data from [Bowlus et al., 2025](https://www.aasld.org/sites/default/files/2025-11/HEP-D-25-00020-1.pdf) using RWD and lab data from [HealthVerity Marketplace.](https://healthverity.com/marketplace/)11  UDCA: ursodeoxycholic acid; SEL: Seladelpar; OCA: obeticholic acid; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase. ## Current research in PBC and how real-world data is being used ### Earlier diagnosis and better risk stratification Because progression can be slow and heterogeneous, a major research focus is predicting “who will progress” and “how fast,” using markers that are measurable in practice. Guidelines emphasize risk stratification, and the field has developed validated prognostic models like the GLOBE and UK-PBC scores, built from large multi-center cohorts and using lab-based variables after UDCA treatment.7 That is an early example of what real-world data can do well in PBC: combine longitudinal follow-up with routine labs to translate biology into decision-grade risk estimates. ### Real-world effectiveness and safety of therapies, including after accelerated approvals With multiple therapies now in play, research questions are more operational: - Which patients are starting UDCA promptly after diagnosis? - How often do patients switch or add-on therapy? - What does biochemical response look like outside trial populations? - What safety signals emerge in broader populations, and how quickly? ### Burden of illness and HEOR questions that trials do not answer well Trials are not designed to quantify the full economic and utilization burden across years of care. Claims-based studies have been used to estimate healthcare resource utilization and costs by line of therapy, and to compare untreated vs treated cohorts in real-world practice.8 That work is helpful for payer and market access questions, but it also surfaces a common rare disease reality: you can estimate costs and utilization at scale, yet still miss key clinical context like lab-based disease activity or symptom severity. ### Data gaps and challenges in PBC research, especially in rare diseases Even with strong scientific momentum, PBC evidence generation runs into familiar rare disease barriers: - Small, fragmented cohorts: Even when prevalence is measurable, the number of “analysis-ready” patients shrinks quickly once you require clean longitudinal follow-up, confirmatory diagnostic signals, therapy exposure windows, and sufficient outcomes time.3 - Missing clinical detail in claims-only datasets: PBC progression and treatment response are often assessed with lab markers (for example alkaline phosphatase and bilirubin) and other clinical variables that may not exist in claims.4,7 - Inconsistent monitoring in routine care: In practice, recommended testing can be uneven, which introduces missingness and makes response evaluation harder. A recent BMJ Open Gastroenterology study highlights that guidelines recommend regular ALP testing to monitor progression and UDCA response, and that adherence to recommended testing intervals can be low.9 - Bias and representativeness issues: Specialty-center cohorts can overrepresent complex patients or advanced disease, which shifts estimates for burden, outcomes, and treatment response. This is not unique to PBC, but it is amplified in rare diseases.10 - Identity and continuity challenges: When a disease requires multi-year follow-up, insurance churn and site-of-care changes can distort “real” outcomes if the patient journey is not stable across sources. These are not just methodological concerns. They determine whether a study yields confident, reproducible conclusions, or ends with “insufficient N,” inconsistent endpoints, and results that are difficult to defend. Recent real-world evidence from [HealthVerity Marketplace](https://healthverity.com/marketplace/) evaluated seladelpar use in nearly 400 patients with primary biliary cholangitis, including those who switched from obeticholic acid after its U.S. withdrawal and those initiating seladelpar as second-line or monotherapy.11 (Figure 1). Across both groups, seladelpar use was associated with meaningful reductions in alkaline phosphatase and high rates of biochemical response, with safety laboratory results remaining stable over short-term follow-up. While follow-up remains limited, these findings illustrate how real-world data can rapidly inform treatment effectiveness and safety in evolving PBC care pathways.11   ## Where real-world data can go further in PBC and where taXonomy Pathways can help If you are trying to generate decision-grade evidence in PBC, the question is not only “Do we have data?” It is “Do we have enough of the right data, for long enough, in a way that holds up under scrutiny?” This is where a rare disease-ready approach to real-world data starts to matter. [taXonomy Pathways](https://healthverity.com/pathways/) was built to unify closed payer claims with lab results and electronic health records (EHR), including physician notes, into research-ready, therapeutic area-specific datasets designed to close evidence gaps.1 In rare diseases specifically, Pathways is intended to bring scale and clinical depth together, without trading off privacy or rigor.12 Below is how that translates to the common evidence problems in PBC. ### Volume: feasibility and power for rare cohorts Rare disease studies often fail before they start because the cohort disappears after eligibility criteria are applied. taXonomy Pathways is anchored by closed payer claims spanning hundreds of payers, nine years of adjudicated history, and more than 300 million patients across pay types.12 That kind of scale can make the difference between a feasible PBC design and an “insufficient N” outcome once you require diagnosis, treatment, and follow-up windows. ### Representativeness: checking referral-center bias PBC care can concentrate in hepatology specialty settings, which can skew observed progression rates, complication patterns, and costs compared to broader community care. Pathways is designed around multi-payer claims coverage across pay types, which supports comparisons that can test how estimates shift by site of care and patient mix, rather than assuming one setting represents all.12 ### Longitudinality: monitoring outcomes that take years to show up PBC is a long-run disease. Questions about progression to cirrhosis, decompensation, transplant, and long-tail cost are inherently longitudinal. With nine years of claims history plus aligned lab and EHR signals, Pathways is positioned for studies that need extended follow-up to capture outcomes that trials often cannot observe at scale.12 ### Stability: reducing small-N instability from cohort churn In rare disease research, minor cohort churn can change cost and outcomes estimates more than teams expect, especially when follow-up is long. A stable longitudinal patient journey across data sources reduces noise and supports reproducibility, which matters when study results will be used in regulatory, payer, or internal governance settings. ### Clinical depth: improving endpoint capture beyond claims-only PBC research depends heavily on lab-based measures and symptom context. taXonomy Pathways includes lab results from two leading outpatient labs representing more than 60% of U.S. testing, with lab values and collection dates aligned to exposure windows from medical and pharmacy claims.11 It also incorporates more than 3.6 billion de-identified clinical notes across 340 million encounters for 43 million patients, capturing symptom-level detail and clinical context that claims do not capture well.12 For PBC, that opens the door to more complete real-world measurement of: - Lab-based disease activity and response signals that define endpoints in many studies.4,7 - Symptoms and reasons for discontinuation that may sit in unstructured notes rather than coded claims. - More credible comparisons of burden and outcomes when the “why” behind a treatment change matters. If you are building PBC evidence and running into small cohorts, missing labs, or inconsistent longitudinal follow-up, request a [taXonomy Pathways](https://healthverity.com/pathways/)walkthrough to see how claims, lab results, and EHR notes can come together into a research-ready PBC patient journey. [![Close the evidence gap with taXonomy Pathways](https://no-cache.hubspot.com/cta/default/5412465/interactive-196135223637.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIiZnfKkG1wZWrEoWU1avcFFDkKOvOIOjnmawPyJtEYkuxvRQMlqFvr%2FKC8kffJUJ3pGl4IHKdNPTsGy24EjMrw3WQ6%2F%2Bdg6XUvhK0IkP%2FxTzg3fyNE9a4S6%2FRNm9YtgzJfCf8f%2BSbyf%2FZlt7EhTqVgO%2FqQ8ccF%2FIyOoiNtJtN6l7FMqhu38gry8pric2SvPi%2FLVUVeZ4Cj&webInteractiveContentId=196135223637&portalId=5412465) ## References 1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). *Primary biliary cholangitis: Definition & facts.* https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/definition-facts 2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). *Primary biliary cholangitis: Treatment.* https://www.niddk.nih.gov/health-information/liver-disease/primary-biliary-cholangitis/treatment 3. Tan JJR, Chung AHL, Loo JH, et al. *Global Epidemiology of Primary Biliary Cholangitis: An Updated Systematic Review and Meta-analysis.* Clinical Gastroenterology and Hepatology. 2025. https://doi.org/10.1016/j.cgh.2025.03.025 4. European Association for the Study of the Liver (EASL). *EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.* Journal of Hepatology. 2017. https://easl.eu/wp-content/uploads/2018/10/PBC-English-report.pdf 5. U.S. Food and Drug Administration (FDA). *Drug Safety Communication (12/12/2024): Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis.* https://www.fda.gov/drugs/drug-safety-and-availability/serious-liver-injury-being-observed-patients-without-cirrhosis-taking-ocaliva-obeticholic-acid-treat 6. Intercept Pharmaceuticals. *Intercept Announces Voluntary Withdrawal of OCALIVA for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold.* September 11, 2025. https://www.globenewswire.com/news-release/2025/09/11/3148535/23024/en/Intercept-Announces-Voluntary-Withdrawal-of-OCALIVA-for-Primary-Biliary-Cholangitis-PBC-from-the-US-Market-US-Clinical-Trials-Involving-Obeticholic-Acid-Placed-on-Clinical-Hold.html 7. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. *Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.* Hepatology. 2018. https://www.aasld.org/sites/default/files/2022-04/PracticeGuidelines-PBC-November2018\_1.pdf 8. Kumar S, Shamseddine N, Yang H, et al. *Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United States.* Advances in Therapy. 2025. https://link.springer.com/article/10.1007/s12325-025-03439-6 9. Gordon SC, Sahota A, Schmidt MA, et al. Assessment of adherence to guidelines for biochemical monitoring and ursodeoxycholic acid treatment response in a retrospective cohort of US patients with primary biliary cholangitis. BMJ Open Gastroenterol. 2025. https://doi.org/10.1136/bmjgast-2025-001899 10. Heredia S, et al. *Real world data for rare diseases research: The beginner’s guide to registries.* Expert Review of Pharmacoeconomics & Outcomes Research. 2023. https://www.tandfonline.com/doi/pdf/10.1080/21678707.2023.2241347 11. Bowlus C, Gordon S, Beltran T, Shen R, Xia F, Kotowsky N, Crittenden D, Frenette C, Chee G, Gao S. Abstract 5037: Real-world experience of seladelpar among patients with primary biliary cholangitis, including patients switched from obeticholic acid. AASLD. 2025 https://www.aasld.org/sites/default/files/2025-11/HEP-D-25-00020-1.pdf 12. HealthVerity. *HealthVerity announces taXonomy Pathways: Closing evidence gaps with the most comprehensive patient journeys.* October 7, 2025. [https://healthverity.com/news/announcing-taxonomy-pathways/](https://healthverity.com/news/announcing-taxonomy-pathways/) 13. Bowlus C, Gordon S, Beltran T, et al. Real-world experience of seladelpar among patients with primary biliary cholangitis, including patients switched from obeticholic acid. Abstract 5037. Presented at: American Association for the Study of Liver Diseases (AASLD) Liver Meeting; 2025.https://www.aasld.org/sites/default/files/2025-11/HEP-D-25-00020-1.pdf [![Explore RWD in HealthVerity Marketplace™](https://no-cache.hubspot.com/cta/default/5412465/interactive-195733501532.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIMea8USHQyVEeHsPqnXi%2BWA97f3UbbssGK5DOFjCd6q4q44HgvVWl1UxJdmxv9smdEXMmmm32DCPNYSv9zZ0EklmOtBsw%2BaJoYFbAXxrRSDR4GCl09wqeR0DEzSDpAHNMyBzan10qcsbT1njnixTalxnYRQ9eKuPV6XVDKKugs1%2BNLtfkcEB9kF5CrTYy5L64E%2BoH9PSkp0Ssk&webInteractiveContentId=195733501532&portalId=5412465) ###### Category - [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices) - [Trends & Insights](https://blog.healthverity.com/tag/trends-insights) - [HEOR](https://blog.healthverity.com/tag/heor) - [Marketplace (RWD)](https://blog.healthverity.com/tag/marketplace-rwd) - [Thought Leadership](https://blog.healthverity.com/tag/thought-leadership) - [Industry Updates](https://blog.healthverity.com/tag/industry-updates) - [Open & Closed Claims](https://blog.healthverity.com/tag/open-closed-claims) - [Case Studies](https://blog.healthverity.com/tag/case-studies) - [Commercial Pharma](https://blog.healthverity.com/tag/commercial-pharma) - [Government](https://blog.healthverity.com/tag/government) - [AI](https://blog.healthverity.com/tag/ai) - [eXOs](https://blog.healthverity.com/tag/exos) - [Audiences](https://blog.healthverity.com/tag/audiences) - [taXonomy Pathways](https://blog.healthverity.com/tag/taxonomy-pathways) - [Clinical Notes](https://blog.healthverity.com/tag/clinical-notes) - [Rare Diseases](https://blog.healthverity.com/tag/rare-diseases) ###### Popular Post - [The GLP-1 trend: What the real-world data reveals](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals) - [GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies) - [Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/open-claims-vs-closed-payer-claims) - [An integrated approach for deeper insight with both open and closed claims data](https://blog.healthverity.com/an-integrated-approach-for-deeper-insight-with-both-open-and-closed-claims-data) - [GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care) ###### Subscribe ### Similar Blogs [![J&J's real-world bladder cancer study started in HealthVerity Marketplace](https://blog.healthverity.com/hs-fs/hubfs/jandj-bladder-cancer-study-featured-alt.png?width=352&name=jandj-bladder-cancer-study-featured-alt.png)](https://blog.healthverity.com/johnson-johnson-real-world-study-using-healthverity-marketplace) #### [J&J's real-world bladder cancer study started in HealthVerity Marketplace](https://blog.healthverity.com/johnson-johnson-real-world-study-using-healthverity-marketplace) [HealthVerity](https://blog.healthverity.com/author/healthverity) 22 July 2025 High-risk NMIBC: Disease overview and treatment approach Johnson & Johnson quickly identified and... [READ MORE](https://blog.healthverity.com/primary-biliary-cholangitis-disease-burden-treatments-and-rwd-gaps) [![Disparities in OUD treatment: Buprenorphine vs. naltrexone](https://blog.healthverity.com/hs-fs/hubfs/oud%E2%80%94treatment-blog-featured.png?width=352&name=oud%E2%80%94treatment-blog-featured.png)](https://blog.healthverity.com/disparities-in-opioid-use-disorder-oud-treatment-buprenorphine-vs.-naltrexone) #### [Disparities in OUD treatment: Buprenorphine vs. naltrexone](https://blog.healthverity.com/disparities-in-opioid-use-disorder-oud-treatment-buprenorphine-vs.-naltrexone) [HealthVerity](https://blog.healthverity.com/author/healthverity) 19 August 2025 Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed... [READ MORE](https://blog.healthverity.com/primary-biliary-cholangitis-disease-burden-treatments-and-rwd-gaps) [![Understanding modern ulcerative colitis through real-world data](https://blog.healthverity.com/hs-fs/hubfs/understanding-modern-ulcerative-colitis-blog.png?width=352&name=understanding-modern-ulcerative-colitis-blog.png)](https://blog.healthverity.com/understanding-modern-ulcerative-colitis-through-real-world-data) #### [Understanding modern ulcerative colitis through real-world data](https://blog.healthverity.com/understanding-modern-ulcerative-colitis-through-real-world-data) [HealthVerity](https://blog.healthverity.com/author/healthverity) 11 December 2025 Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic... [READ MORE](https://blog.healthverity.com/primary-biliary-cholangitis-disease-burden-treatments-and-rwd-gaps) #### Who we serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) #### How we help - [HealthVerity Marketplace](https://healthverity.com/marketplace/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/) - [HealthVerity FLOW](https://healthverity.com/flow/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) #### Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) #### Our company - [About Us](https://healthverity.com/about-us/) - [Leadership](https://healthverity.com/about-us/#leadership) - [Board of Directors](https://healthverity.com/about-us/#board) - [Careers](https://healthverity.com/careers/) - [Contact](https://healthverity.com/contact/) ©2026 HealthVerity, Inc.    |    [Terms & Conditions](https://healthverity.com/terms-and-conditions/)    |    [Privacy Policy](https://healthverity.com/privacy-policy/) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "articleSection" : "Rare Disease Research", "author" : { "@type" : "Person", "name" : "Laura Budurlean" }, "dateModified" : "2026-01-23", "datePublished" : "2026-01-23", "description" : "An in-depth review of primary biliary cholangitis (PBC), examining disease burden, current and emerging treatments, real-world evidence, research gaps, and how integrated data can improve evidence generation in rare autoimmune liver diseases.", "headline" : "Primary biliary cholangitis in the real world: Disease burden, treatments and gaps", "keywords" : [ "Primary biliary cholangitis", "PBC", "rare disease research", "real-world evidence", "autoimmune liver disease", "UDCA", "seladelpar", "elafibranor", "health economics", "taXonomy Pathways", "HealthVerity" ], "mainEntityOfPage" : { "@id" : "https://blog.healthverity.com/primary-biliary-cholangitis-disease-burden-treatments-and-rwd-gaps", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.healthverity.com/hubfs/healthverity-logo.png" }, "name" : "HealthVerity" }, "url" : "https://blog.healthverity.com/primary-biliary-cholangitis-disease-burden-treatments-and-rwd-gaps" } ``` ```json { "@context" : "https://schema.org", "@type" : "FAQPage", "mainEntity" : [ { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease caused by immune-mediated destruction of the small bile ducts in the liver, leading to cholestasis, fibrosis, cirrhosis, and potentially liver failure." }, "name" : "What is primary biliary cholangitis?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Ursodeoxycholic acid (UDCA) is the recommended first-line therapy for PBC. Newer therapies such as elafibranor and seladelpar have received FDA accelerated approval for patients with an inadequate response to UDCA or who cannot tolerate it." }, "name" : "What treatments are currently available for primary biliary cholangitis?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Because PBC is a rare, slowly progressive disease, real-world data is essential for evaluating long-term effectiveness, safety, treatment durability, and disease burden outside controlled clinical trials." }, "name" : "Why is real-world data important for PBC research?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Key challenges include small patient populations, fragmented data sources, missing laboratory values in claims-only datasets, inconsistent monitoring in routine care, and limited longitudinal follow-up." }, "name" : "What are the main data challenges in studying primary biliary cholangitis?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Datasets that integrate claims, laboratory results, and electronic health records provide greater clinical depth, improved longitudinal stability, and more reliable endpoint capture, enabling more defensible PBC research." }, "name" : "How can integrated real-world datasets improve evidence generation in PBC?" } ] } ``` ```json { "@context" : "https://schema.org", "@type" : "BreadcrumbList", "itemListElement" : [ { "@type" : "ListItem", "item" : "https://healthverity.com/", "name" : "Home", "position" : 1 }, { "@type" : "ListItem", "item" : "https://blog.healthverity.com/", "name" : "Blog", "position" : 2 }, { "@type" : "ListItem", "item" : "https://blog.healthverity.com/primary-biliary-cholangitis-disease-burden-treatments-and-rwd-gaps", "name" : "Primary biliary cholangitis in the real world: Disease burden, treatments and gaps", "position" : 3 } ] } ```